Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of a strain of Lactobacillus rhamnosus in preventing and relieving ulcerative colitis

A technology of Lactobacillus rhamnosus and ulcerative colitis, applied in the field of functional microorganisms, can solve the problems of poor effect and few strains

Active Publication Date: 2022-08-02
JIANGNAN UNIV
View PDF8 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] In view of the problem that currently there are few bacterial strains that can be used to alleviate the symptoms of ulcerative colitis, or the effect is not good, the present invention has screened out probiotics that can effectively relieve symptoms related to ulcerative colitis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of a strain of Lactobacillus rhamnosus in preventing and relieving ulcerative colitis
  • Application of a strain of Lactobacillus rhamnosus in preventing and relieving ulcerative colitis
  • Application of a strain of Lactobacillus rhamnosus in preventing and relieving ulcerative colitis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0052] Example 1: Tolerance of Lactobacillus rhamnosus CCFM1129 to simulated gastrointestinal fluids

[0053] The cryopreserved Lactobacillus rhamnosus CCFM1129 was inoculated into the mMRS plate, cultured anaerobic at 37°C for 48 hours, and then subcultured with the mMRS medium for 2 to 3 times to obtain the culture medium of Lactobacillus rhamnosus CCFM1129.

[0054] Take 1 mL of Lactobacillus rhamnosus CCFM1129 culture solution, mix it with 9.0 mL of pH 2.5 artificial simulated gastric juice (mMRS medium containing 1% pepsin, pH = 2.5), and culture it anaerobically at 37 °C for 0 h, Samples were taken at 0.5h, 1h, 2h and 3h, and the plate colonies were counted with mMRS agar medium for pouring and culture, and the number of viable bacteria was determined and the survival rate was calculated.

[0055] Take 1 mL of Lactobacillus rhamnosus CCFM1129 culture medium and add it to 9 mL of artificial simulated intestinal fluid (mMRS medium containing 0.3% bovine bile salts, 1% tryp...

Embodiment 2

[0061] Example 2: Lactobacillus rhamnosus CCFM1129 has no toxic and side effects on C57BL / 6J mice

[0062] Lactobacillus rhamnosus CCFM1129 was resuspended in 3g / 100mL sucrose solution to make a concentration of 5.0×10 9 CFU / mL bacterial suspension. Take 6 healthy male C57BL / 6J mice with a weight of about 14-16g, and after a week of acclimatization, the bacterial suspension of this concentration is given once a day (0.2mL for each gavage), observed for one week, and the death and body weight are recorded. .

[0063] The results of these tests are listed in Table 3. These results show that the feeding concentration of 5.0 × 10 9 The Lactobacillus rhamnosus CCFM1129 of CFU / mL did not have obvious effects on the mice, and there was no significant change in body weight and no death phenomenon. The mice showed no obvious pathological symptoms.

[0064] Table 3 Changes in body weight and death of mice

[0065] time (days) 1 2 3 4 5 6 7 Weight (g) 19.53±0...

Embodiment 3

[0067] Example 3: Effects of Lactobacillus rhamnosus CCFM1129 on disease symptoms in UC mice:

[0068] Thirty healthy male C57BL / 6J mice weighing 14-16g were taken, acclimated to the environment for 1 week, 6 mice in each group, and randomly divided into 5 groups: blank group, model group, drug group, Lactobacillus rhamnosus CCFM1129 intervention group (CCFM1129), Lactobacillus rhamnosus FXJWS44-L2 control group (FXJWS44-L2). The dose of gavage bacterial suspension is 5.0×10 9 CFU / mL, resuspended in 3g / 100mL sucrose solution, 0.2mL per gavage. At week 5, dextran sulphate sodium (DSS) was added to drinking water at a final concentration of 2.5 g / 100 mL for 7 days to induce colitis in mice. The groups and treatment methods of experimental animals are shown in Table 4:

[0069] Table 4 Animal grouping and treatment methods

[0070]

[0071] During the fifth week, during the modeling period (during DSS treatment), the mice were weighed regularly every day and the percentage...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
thicknessaaaaaaaaaa
Login to View More

Abstract

The invention discloses the application of a strain of Lactobacillus rhamnosus in preventing and relieving ulcerative colitis, and belongs to the technical field of functional microorganisms. Lactobacillus rhamnosus can tolerate the human gastrointestinal environment, significantly reduce weight loss during ulcerative colitis, improve stool texture and blood in the stool, improve colonic mucosal damage, reduce MPO activity, and reduce the pro-inflammatory factor TNF-α in the colon , IL-1β, IL-6, IFN-γ content, up-regulate the transcription levels of colon tight junction-related proteins Claudin-3, ZO-1, ZO-2 and Occludin, antimicrobial peptides Reg3g, Reg3b and mucin MUC2, increase the transcription level of short chain The abundance of fatty acid-producing bacteria Coprococcus, Faecalibacterium and the content of short-chain fatty acids increased the abundance of beneficial bacteria Lactobacillus and decreased the abundance of opportunistic pathogen Acinetobacter, increasing the richness and diversity of intestinal flora.

Description

technical field [0001] The application of a strain of Lactobacillus rhamnosus in preventing and relieving ulcerative colitis belongs to the technical field of functional microorganisms. Background technique [0002] Ulcerative colitis (UC) is a type of inflammatory bowel disease (IBD). UC is a continuous inflammation of the colonic mucosa and submucosa, and the disease usually spreads from the rectum to the entire colon. UC has a long course of disease and is prone to recurrence, which not only affects the quality of life of patients, but also increases the risk of bowel cancer. At present, the pathogenesis of UC is still unclear. Studies have shown that it is mainly related to immune factors, intestinal flora, genetic factors and environmental factors. , self-antigens, etc. produce an unrestricted immune response, thereby triggering inflammation and a series of disease symptoms. [0003] There are three commonly used UC treatment drugs, aminosalicylic acid, hormones and ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C12N1/20A61K35/747A61P1/00A61P1/04A23L33/135A23L29/00A23C9/123A23L11/50A23C13/16A23C19/00A23L19/00C12R1/225
CPCA61K35/747A61P1/00A61P1/04A23L33/135A23L29/065A23C9/1234A23C13/16A23C19/00A23L19/00A23V2002/00A23V2400/175A23V2200/3204
Inventor 王刚郑雨星王琳琳翟齐啸陆文伟于雷雷张秋香崔树茂杨波毛丙永唐鑫赵建新张灏陈卫
Owner JIANGNAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com